VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2021 | Rebastinib plus paclitaxel shows encouraging anti-tumor activity in endometrial cancer

Filip Janku, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the safety and efficacy data from a Phase Ib/II study of rebastinib combined with paclitaxel in advanced/metastatic endometrial cancer. The open-label study, which also investigated 4 other disease-specific cohorts, enrolled 38 patients with endometrial cancer, with 33 patients evaluable after a median 5.9 months of follow-up. The combination of 50 mg BID rebastinib and paclitaxel showed encouraging preliminary efficacy in this heavily pretreated patient population. Adverse events were mostly of low grade and serious adverse events were resolved with dose interruption. These initial findings warrant continued investigation of the combination in patients with endometrial cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Disclosures

Filip Janku, MD, PhD has research support from Astex, Novartis, BioMed Valley Discoveries, Fore Bio, Deciphera, Bristol-Myers Squibb, Asana, Ideaya Biosciences, Sanofi, Merck, F-star, JSI Innopharm, Bioxcel, Lilly, Bicara, PureTech Health, FujiFilm Pharmaceuticals, Sotio, Synlogic, NextCure, Hutchinson Medipharma; is on the Scientific Advisory Boards of Ideaya Biosciences, Synlogic, Sotio, Puretech Health, Deciphera, Crown Bioscience, Asana, Fore Bio, Novartis, Bicara, and PegaOne; is a paid consultant for Mersana Therapeutics, Flame Bio, Cardiff Oncology, MedinCell, and Immunomet; and has ownership interests in Cardiff Oncology.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter